Pharmaceutical

Hoth and Aronnax partner for HT-KIT cancer therapy development

Hoth Therapeutics has announced a master services agreement with Aronnax to advance the development of its HT-KIT cancer therapeutic.

Aug 17, 2024 - 04:00
Hoth and Aronnax partner for HT-KIT cancer therapy development
Hoth Therapeutics has announced a master services agreement with Aronnax to advance the development of its HT-KIT cancer therapeutic.
Read the original article

Tags:

Previous Article

Lykos cuts team by 75%, vows to keep MDMA program despite FDA veto

Next Article

FDA accepts Deciphera’s vimseltinib NDA for priority review

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA accepts Ipsen’s sNDA for mPDAC therapy

FDA accepts Ipsen’s sNDA for mPDAC therapy

Jun 15, 2023

Violet CEO on measuring clinician inclusiveness: ‘It’s almost like a credit score’

Violet CEO on measuring clinician inclusiveness: ‘It’s ...

Dec 27, 2023

STAT+: European regulator will review study data from contract research organization due to ‘serious concerns’

STAT+: European regulator will review study data from c...

Jul 22, 2023